Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. Different mechanisms of acquired resistance to third-generati...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Marti, A, Felip, E, Matito, J, Mereu, E, Navarro, A, Cedrés, S, Pardo, N, Martinez de Castro, A, Remon, J, Miquel, J M, Guillaumet-Adkins, A, Nadal, E, Rodriguez-Esteban, G, Arqués, O, Fasani, R, Nuciforo, P, Heyn, H, Villanueva, A, Palmer, H G, Vivancos, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834054/
https://www.ncbi.nlm.nih.gov/pubmed/28961841
http://dx.doi.org/10.1093/annonc/mdx396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834054/
https://www.ncbi.nlm.nih.gov/pubmed/28961841
http://dx.doi.org/10.1093/annonc/mdx396

Ejemplares similares